Cryptosporidium (genus)

Cryptosporidium is a genus of protozoan parasites (phylum Apicomplexa) that infect the gastrointestinal tract of vertebrates, including humans, causing the diarrheal disease cryptosporidiosis[1][3][5]. The life cycle features both asexual and sexual stages, with environmental transmission via hardy, sporulated oocysts[1][3]. Two main species, Cryptosporidium parvum and Cryptosporidium hominis, are responsible for most human infections, while other species infect a variety of animal hosts[1][3][5]. Infection is primarily transmitted through contaminated water, occasionally food, and can cause severe or life-threatening gastroenteritis, especially in immunocompromised individuals[3][5]. Although several drugs show activity against Cryptosporidium (e.g., nitazoxanide, statins, bumped kinase inhibitors), no treatment is uniformly effective, particularly in AIDS patients[3][2][4]. Therapeutic research focuses on targeting parasite-specific metabolic pathways and kinases, but most molecular approaches recognize species- or pathway-level targets rather than treating the genus as a conventional “molecular target.”[2][4] Note: Cryptosporidium is not a *molecular target* but a genus of protozoan parasites. The query refers to a taxonomic entity, not a receptor, enzyme, transporter, or molecular therapeutic target. The actual molecular drug targets against Cryptosporidium include kinases (e.g., CDPK1), metabolic enzymes, or transcription factors specific to the parasite, not the genus itself[2][4]. For drug-targeting efforts, refer to specific proteins within Cryptosporidium, such as “calcium-dependent protein kinase 1 (CDPK1) from Cryptosporidium parvum.”

Other names

CryptoCryptosporidiaCryptosporidium species (e.g., Cryptosporidium parvum, Cryptosporidium hominis)

Inhibition of metabolic enzymes (e.g., HMG-CoA reductase), Inhibition of key parasite kinases (e.g., CDPK1 inhibition by BKIs), Inhibition of protein synthesis (aminoacyl-tRNA synthetase inhibitors), General antiparasitic activity (Nitazoxanide), Inhibition of parasite transcription factors (e.g., Myb-M, experimental) [2][4]